Market revenue in 2023 | USD 427.5 million |
Market revenue in 2030 | USD 664.3 million |
Growth rate | 6.5% (CAGR from 2023 to 2030) |
Largest segment | Targeted therapy |
Fastest growing segment | Immunotherapy |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Chemotherapy, Immunotherapy, Targeted Therapy, Hormonal Therapy |
Key market players worldwide | Novartis AG ADR, Pfizer Inc, Merck KGaA, Janssen Pharmaceuticals, Celgene, Roche Holding AG, AstraZeneca PLC, AbbVie Inc, Bristol-Myers Squibb Co, Macrogenics Inc, Celldex Therapeutics Inc, Sanofi SA, Amgen Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to breast cancer drugs will help companies and investors design strategic landscapes.
Targeted therapy was the largest segment with a revenue share of 64.23% in 2023. Horizon Databook has segmented the Canada breast cancer drugs based on chemotherapy, immunotherapy, targeted therapy, hormonal therapy covering the revenue growth of each sub-segment from 2018 to 2030.
Breast cancer is the second leading cause of death among Canadian women. According to the Canadian Cancer Society, it is estimated that in 2019, about 26,900 new cases were diagnosed and around 5,000 women died due to this disease.
In addition, approximately 230 men were diagnosed with this cancer and 55 died from it. Furthermore, growing awareness coupled with increasing incidence is anticipated to drive the market. For instance, Breast Cancer Society of Canada, a registered national nonprofit charity, raises funds to support research for diagnosis and treatment of breast cancer.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada breast cancer drugs, including forecasts for subscribers. This country databook contains high-level insights into Canada breast cancer drugs from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account